Navigation Links
New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year
Date:11/2/2007

CHAPEL HILL, N.C., Nov. 2 /PRNewswire/ -- Just how much of the time that sales people should be spending with the customer is lost due to administrative tasks and internal communication?

Pharmaceutical sales directors agree the answer is 'too much time' - in fact, 32% of the time used for internal communication - or 6 weeks per rep per year - is unnecessary and causes millions in lost sales every year, according to a recent research study by Best Practices, LLC. But yet, understanding and implementing the key tactics that make a more productive sales force remains a daily challenge.

The report, "Pharma Sales Force Effectiveness: Increasing Productivity Through Streamlined Internal Communication," (free report excerpt at: http://www3.best-in-class.com/rr873.htm) highlights specific practices and performance metrics you can implement today to see immediate results in sales team efficiency and bottom-line revenues.

Findings were collected from surveys and interviews with sales leaders and field sales staff at leading companies, including: Pfizer, Sanofi-Aventis, Purdue Pharma, Janssen, Merck, Eli Lilly, Johnson & Johnson, Ortho-McNeil, Genentech and Allergan.

This report is packed with sales communication metrics and productivity practices. Some of them include:

- Poorly prioritized or redundant communication between pharma sales reps

and their managers causes an estimated $309,000 in annual lost sales

per sales rep.

- Pharma sales reps spend an average of 13.7 hours a week managing

internal communication. Most of this time is spent managing email,

checking voicemail and talking on a cell phone. Of this time, 4.4 hours

(or 32%) are perceived to be unnecessary.

- District managers estimated that they spent 36.5 hours per week

managing internal communication. That's an amazing 1,825 hours per year'/>"/>

SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...e aged men who would like to grow old in good heal... education, and a wife, according to a recent stud...ican men living in the US state of Hawaii revealed...edictors of which middle-aged men would live healt...
...lergic reaction has been widely reported by women ... associated with burning in their groin and genita...onfirmed by doctors as a true case of allergy that...ankfully doctors have given the hope to such women...
...than 80,000 people in the United States are on wai...o wait for the death of a matching donor, but more...g donors. Last year nearly 7,000 people donated a...of a lung to help someone in need of a transplant....
...enes of progeny are dependant on a fairly simple f...potent enough to impact the genes of the future ge...hers, supplements consumed by expectant mice were ...s. The findings appear in the Proceedings of the N...
Other Medicine News:Health News:Keys to Good Health in Old Age Begins in Midlife 2Health News:See, men cause allergies in women after sex 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 3
(Date:10/7/2008)...e-FirstCall/ - Burcon NutraScience,Corporation (TS...Supertein(TM) canola protein isolates are GRAS (Ge... in a variety of food and beverage,applications. T...n,independent evaluation by a panel of qualified e...utritional sciences, food allergies and pediatric,...
(Date:10/7/2008)...at ACG Annual Scientific Meeting -, ORLANDO, Fla....ceuticals, Inc. (formerly Microbia, Inc.) and Fore...d the presentation of results from a Phase,2b stud...20 patients with,irritable bowel syndrome with con...that once- daily oral dosing of linaclotide, acros...
(Date:10/7/2008)...e-FirstCall/ -- Ardea Biosciences, Inc.,(Nasdaq: ...A119, a Potent,and Highly Selective MEK1/2 Inhibit...- induced Chronic Colitis in Mice," was presented ...2008 Annual Meeting in Orlando,Florida. The poste...,RDEA119, the Company,s lead mitogen-activated ERK...
(Date:10/6/2008)...ewswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: V... joining the,Company as Vice President of Investor... will be responsible for all investor relations,fu...l Officer Kurt,Leutzinger., Most recently, Dr. Sm...Analyst at JPMorgan Securities, and has been an an...
Breaking Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3New Drug Application for Tolvaptan Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia Accepted by the U S Fo 2362 1New Drug Application for Tolvaptan Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia Accepted by the U S Fo 2362 2New Drug Application for Tolvaptan Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia Accepted by the U S Fo 2362 3Senesco Technologies Closes on Additional 244 0 Million of Previously Announced Financing 2360 1Senesco Technologies Closes on Additional 244 0 Million of Previously Announced Financing 2360 2Senesco Technologies Closes on Additional 244 0 Million of Previously Announced Financing 2360 3Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 1Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 2Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 3Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 4Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 5FDA to Extend Review of Data Quality Submission for Genasense 28R 29 in Melanoma 1115 1FDA to Extend Review of Data Quality Submission for Genasense 28R 29 in Melanoma 1115 2FDA to Extend Review of Data Quality Submission for Genasense 28R 29 in Melanoma 1115 3
...a Trial to 9 mg Dosage,Level, HOPKINTON, Mass., Ap... Sciences announced today that clinical data on it...ented in the Neurotrauma,and Critical Care Scienti...ican Association of Neurological Surgeons (AANS) i...s of the Cethrin Phase I/IIa,Prospective Clinical ...
...ire-FirstCall/ -- Kosan,Biosciences Incorporated t...t-generation epothilone, showing a high level of,a...and safety,profile in a broad range of in vitro te...hemically engineered to have a favorable,tissue di... to,result in excellent tumor penetration and a lo...
Other Medicine Technology:Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons 2Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons 3Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons 4Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR 2Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR 3
... of deflectable curve catheters designed to specif...r patients with small anatomies. Each catheter is ... the finest materials. A unique multi-step process...ion technologies results in the excellent torque a...
... of fixed curve catheters designed to specifically...ents with small anatomies. Each catheter is handcr...inest materials. A unique multi-step process that ...chnologies results in the excellent torque and fle...
4Fr, 5Fr & 6Fr diagnostic electrophysiology catheters with fixed curves.
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism.
Medicine Products: